AFC
MRNA icon

Ares Financial Consulting’s Moderna MRNA Stock Holding History

Ares Financial Consulting’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95K Hold
85
– – ﹤0.01% 675
2026
Q1 		$4.25K Buy
+85
New +$3.97K ﹤0.01% 714

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Ares Financial Consulting's MRNA Position: Q2 2026 in Review

Ares Financial Consulting held its Moderna (MRNA) position steady in Q2 2026 at 85 shares worth $5.95K. The position accounts for ﹤0.01% of the portfolio, ranked #675.

Ares Financial Consulting first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 364 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Ares Financial Consulting held 85 shares of Moderna worth $5.95K as of Q2 2026.
  • Ares Financial Consulting left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #675 holding.
  • Ares Financial Consulting first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
  • 364 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.